eligibility_summary
Eligibility: Advanced solid tumor with measurable disease (RECIST v1.1), ECOG 0–1, adequate organ function. Exclude: unresolved >Grade 1 toxicities, anticancer therapy within 14 d (small molecules) or 28 d (biologics), progressive/symptomatic brain mets, serious uncontrolled illness/infection, significant cardiac disease, MDS/AML, other cancers within 3 y (except low-risk: treated skin BCC/SCC, DCIS, prostate Gleason ≤6), pregnant or breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: TORL-4-500, an intravenous antibody–drug conjugate (ADC, targeted biologic linked to a cytotoxic small‑molecule payload) dosed every 3 weeks. Mechanism of action: The monoclonal antibody component binds a tumor-associated cell‑surface antigen, is internalized, and releases its cytotoxic payload inside the cancer cell, leading to cell death, a bystander effect may occur. Drug type: ADC (targeted therapy). Cells/pathways targeted: Antigen‑positive tumor cells in advanced solid tumors (including hepatocellular carcinoma). The specific antigen/pathway is not disclosed in the registry, targeting relies on antigen-mediated internalization rather than a defined signaling pathway. Purpose: First‑in‑human Phase 1 assessing safety, tolerability, PK, and preliminary antitumor activity.